Dermatology practice acquisition generates the highest per-wRVU compensation of any medical specialty at $72 per work unit, yet the specialty experienced a 5-11% pay decline in 2024 while PE involvement exceeds 30% of practices and second-wave "consolidation of consolidators" mergers accelerate (Source: Marit Health, 2025; Doximity, 2025; AMGA, 2025; NIHCM/Health Affairs, 2024). AQUA, Platinum, Qualderm, and Schweiger completed strategic platform mergers in 2024-2025, narrowing the pool of remaining independent targets (Source: Healthcare Business Today, 2025). Talyx's physician intelligence graph tracks 66,887 physicians across all 50 U.S. states and 61,944 healthcare facilities, delivering the intelligence infrastructure dermatology platforms require to identify acquisition targets and recruit physicians in an increasingly consolidated market.
Dermatology presents a relatively balanced national workforce profile that is beginning to show signs of erosion. HRSA projected 99% workforce adequacy for dermatology through 2035, but the updated 2038 model shows a decline to 95% -- a 5% shortfall that represents early warning of supply constraints (Source: HRSA, 2022; HRSA, 2025).
The overall U.S. physician workforce faces a projected shortage of 13,500 to 86,000 by 2036 (Source: AAMC, 2024). While dermatology is not among the most shortage-affected specialties, the 4-percentage-point decline in projected adequacy between HRSA models suggests that demographic pressures -- particularly the aging population driving increased skin cancer screening demand -- are beginning to outpace supply growth.
Patient appointment wait times have surged 19% since 2022 and 48% since 2004 across all specialties, with dermatology among the longer-wait specialties due to the breadth of conditions treated and limited physician supply (Source: AMN Healthcare, 2025).
| Metric | Value | Source |
|---|---|---|
| MGMA Median Total Compensation | ~$495,000 | MGMA 2024 (estimated) |
| Doximity Average Compensation | $508,401 | Doximity 2025 Report |
| Year-over-Year Change | -5.0% (Doximity); -11% (AMGA) | Doximity, 2025; AMGA, 2025 |
| $/wRVU Rate | ~$72 (highest of any specialty) | Marit Health, 2025 |
| Academic $/wRVU | ~$48 | Marit Health, 2025 |
Dermatology presents a unique compensation profile: it commands the highest compensation per wRVU of any medical specialty at approximately $72/wRVU, reflecting the high-value, procedure-intensive nature of dermatologic care (Source: Marit Health, 2025). However, the specialty experienced the largest pay decline of any specialty in 2024 -- down 5% per Doximity and 11% per AMGA -- potentially reflecting market recalibration as PE consolidation matures and competition dynamics shift (Source: Doximity, 2025; AMGA, 2025).
The $24/wRVU gap between private practice ($72) and academic ($48) dermatology underscores the financial incentive for dermatologists to practice in private or PE-backed settings rather than academic medical centers.
Dermatology residency maintains an approximately 99%+ fill rate, placing it among the most competitive Main Match specialties alongside orthopedic surgery (Source: NRMP, 2025). International medical graduates face extremely low match rates into dermatology, and the specialty remains one of the most selective residencies in all of medicine. This selective pipeline produces a limited annual supply of new dermatologists, constraining growth and intensifying competition for available physicians.
Dermatology generates high revenue per physician through a combination of medical dermatology (skin cancer screening, biopsies, Mohs surgery), cosmetic services (injectables, laser treatments, body contouring), and dermatopathology. The specialty's highest-in-medicine $/wRVU rate of $72 means each unit of physician work translates to more revenue than in any other specialty.
Revenue loss from a vacant dermatology position accumulates at $7,000-$9,000 per day (Source: CompHealth, 2024). For practices with cosmetic service lines, the revenue impact may be even higher due to the elective, cash-pay nature of cosmetic procedures.
Dermatology PE consolidation has entered a distinct second phase. The first wave (2012-2022) saw PE firms acquire independent practices and build regional platforms. The second wave (2023-present) features:
Global PE healthcare deal value reached $190 billion in 2025, a record, with sponsor-to-sponsor transactions exceeding 150 deals (Source: Bain & Company, 2026). Dermatology recapitalizations are expected to accelerate in 2026 as several large platforms approach exit timelines.
Overall healthcare services EBITDA multiples declined to a median of 11.5x in 2025, down from 14.5x in 2024 (Source: FOCUS Investment Banking, 2025). However, specialty-specific dynamics vary. Practices with diversified revenue streams (medical, cosmetic, Mohs surgery, dermatopathology) and strong commercial payer mixes maintain premium valuations. Commercial payer mix drives 40-60% higher multiples versus Medicaid-heavy practices (Source: FOCUS Investment Banking, 2025).
NPI Registry and CMS Data: Taxonomy code filtering for dermatology (207N00000X), dermatopathology (207NP0225X), Mohs surgery, and pediatric dermatology. CMS utilization data reveals procedure volumes, biopsy rates, and Mohs surgery case counts.
Cosmetic Revenue Indicators: Practice website analysis, RealSelf profiles, social media presence (Instagram), and patient review platforms reveal cosmetic service mix -- injectables (Botox, fillers), laser treatments, and elective procedures that contribute non-insurance revenue streams.
Practice Ownership and PE Affiliation Data: State corporate filings, MSO registration records, and PE transaction databases identify practices already under PE ownership, recently acquired practices, and remaining independent groups -- critical for acquisition target identification.
Dermatopathology Laboratory Data: CMS laboratory enrollment records, CLIA certificates, and pathology billing data identify practices operating in-house dermatopathology labs -- a high-margin ancillary service that drives premium valuations.
Professional Society Monitoring: AAD (American Academy of Dermatology), ASDS (American Society for Dermatologic Surgery), and ACMS (American College of Mohs Surgery) membership, leadership positions, and meeting participation.
Residency Pipeline Tracking: ACGME-accredited dermatology residency programs, fellowship programs (dermatopathology, Mohs, cosmetic), and academic medical center graduation announcements.
Advanced Consolidation Limits the Independent Practice Pool: With PE involvement exceeding 30% of dermatology practices and the "consolidation of consolidators" underway, the pool of independent practices available for acquisition or physician recruitment is shrinking (Source: NIHCM/Health Affairs, 2024). Each successive acquisition reduces the universe of remaining targets.
Compensation Decline Creates Recruitment Uncertainty: Dermatology experienced the largest compensation decline of any specialty in 2024, with Doximity reporting a 5% decrease and AMGA reporting an 11% decline (Source: Doximity, 2025; AMGA, 2025). This volatility creates hesitancy among candidates evaluating compensation offers and complicates benchmarking against rapidly shifting market data.
Cosmetic vs. Medical Dermatology Candidate Segmentation: Platforms with significant cosmetic service lines require dermatologists with cosmetic training, aesthetic sensibility, and patient-facing marketing capabilities. This subset of the dermatology workforce carries distinct competency requirements and compensation expectations that standard recruitment channels do not differentiate.
Non-Compete Clause Prevalence: Dermatology practices -- particularly those with PE backing -- frequently include non-compete clauses in physician employment agreements. Recruiting dermatologists from competing platforms requires intelligence on non-compete terms, geographic restrictions, and enforceability by state jurisdiction.
Dermatopathology and Mohs Surgeon Scarcity: Dermatopathologists and Mohs surgeons represent narrow subspecialty pools with limited annual fellowship output. Practices operating in-house dermatopathology laboratories or Mohs surgery programs require these subspecialists to maintain high-margin service lines, creating acute recruitment pressure for a very small candidate universe.
| Metric | Description | Intelligence Value |
|---|---|---|
| Procedure Mix (Medical/Cosmetic/Surgical) | Distribution across medical derm, cosmetic procedures, and Mohs surgery | Revenue composition and platform fit assessment |
| Cosmetic Revenue Percentage | Estimated non-insurance revenue from elective cosmetic procedures | Revenue quality and growth trajectory |
| Dermatopathology Lab Operation | In-house lab with CLIA certification and pathology billing | Ancillary revenue and valuation premium assessment |
| wRVU Production and $/wRVU Rate | Annual work output and compensation efficiency | Productivity benchmarking ($72 private vs. $48 academic) |
| PE Affiliation Status | Independent, PE-backed platform, hospital-employed | Acquisition and recruitment approach optimization |
| Non-Compete Clause Intelligence | Scope, duration, and geographic restriction of existing agreements | Recruitment feasibility and timing assessment |
| Online Reputation and Patient Reviews | Google, Healthgrades, RealSelf ratings and review volume | Brand value and patient acquisition capability |
| Practice Size and Growth Trajectory | Physician count, APP staffing, location count, revenue trend | Acquisition target scoring and expansion potential |
Dermatology Practice Acquisition Scorecards: Talyx's physician intelligence infrastructure provides dermatology-specific recruitment and retention analytics. Multi-source practice-level intelligence combines physician demographics, revenue composition (medical/cosmetic/surgical), ancillary services (dermatopathology, Mohs), payer mix, and competitive positioning for prospective acquisitions.
Dermatologist Candidate Dossiers: Individual physician profiles integrating CMS data, cosmetic service indicators, professional network maps, PE affiliation history, non-compete analysis, and behavioral mobility signals.
Consolidation Landscape Monitoring: Real-time intelligence on dermatology platform M&A activity, recapitalization announcements, platform merger dynamics, and competitive physician recruitment campaigns.
Residency and Fellowship Pipeline Reports: Annual analysis of dermatology, dermatopathology, and Mohs surgery program graduates by geography, institutional affiliation, and early career trajectory.
Cosmetic Market Intelligence: MSA-level analysis of cosmetic dermatology market dynamics, competitive positioning, patient demand indicators, and revenue opportunity assessment for platforms expanding cosmetic service lines. According to Talyx intelligence data, California (6,609 physicians), Florida (1,945), Texas (1,758), New York (1,331), and Pennsylvania (938) represent the five largest physician markets in Talyx's intelligence graph -- geographic concentrations that shape dermatology platform expansion priorities.
Retention Risk Assessment: Monitoring of employed dermatologists for turnover indicators including compensation gap analysis (accounting for recent specialty-wide declines), non-compete expiration timelines, and professional profile activity. PE platforms using Talyx's intelligence infrastructure gain dermatology market visibility including compensation benchmarks, competitive positioning, and recruitment pipeline data. Talyx's capability transfer model ensures dermatology intelligence becomes a permanent organizational capability owned by the client.
Dermatology ranks among the most PE-consolidated physician specialties, with PE involvement exceeding 30% of practices and single PE firms exceeding 30% market share in 108 MSA specialty markets (Source: NIHCM/Health Affairs, 2024; Health Affairs, 2024). The specialty has entered a second wave of consolidation: AQUA, Platinum, Qualderm, and Schweiger completed strategic platform mergers in 2024-2025, and new strategic buyers -- pharmaceutical distributors and health insurers -- are acquiring PE-built platforms. Dermatology recapitalizations are expected to accelerate in 2026 as platforms approach exit windows.
Dermatology experienced the largest compensation decline of any specialty in 2024 -- Doximity reports a 5% decrease to $508,401 and AMGA reports an 11% decline -- driven by PE consolidation compressing owner-operator compensation, mid-level provider competition, and reimbursement pressure on biopsy codes (Source: Doximity, 2025; AMGA, 2025). Despite the decline, dermatology maintains the highest $/wRVU rate of any specialty at $72 per work unit (Source: Marit Health, 2025). Talyx tracks these benchmarks to help PE platforms calibrate competitive offers during a volatile compensation period.
Talyx maps dermatology ownership by cross-referencing state corporate filings, MSO registration records, NPI group enrollment data, PE transaction databases, and CMS group reassignment data against the full NPI-registered dermatologist population in each target MSA. This structured OSINT methodology identifies the diminishing pool of independent practices that every competing platform is seeking. Talyx's intelligence infrastructure profiles 11,628 companies including 2,062 healthcare organizations, providing complete competitive landscape visibility for acquisition targeting.
Schedule a strategic briefing to discuss how Talyx can build intelligence infrastructure for your organization.
Schedule a Briefing